The major protocol features of the immature rat uterotrophic assay have been evaluated using a range of reference chemicals. The protocol variables considered include the selection of the test species and route of chemical administration, the age of the test animals, the maintenance diet used and the specificity of the assay for estrogens. It is concluded that three daily oral old rats, followed by determination of absolute uterus weights on the fourth day, provides a sensitive and toxicologically relevant in vivo estrogenicity assay. Rats are favoured over mice for reasons of toxicological practice, but the choice of test species is probably not a critical protocol variable, as evidenced by the similar sensitivity of rats and mice to the uterotrophic activity of methoxychlor. Vaginal opening is chemicals to reduce or abolish the uterotrophic response of estradiol is suggested to provide a useful extension of the uterotrophic assay fo
SUMMARY
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The results of a series of studies on the environmental estrogen nonylphenol (NP), and its ng of the aliphatic sidechain is important for activity. 17 similar activity to estradiol in the uterotrophic assay, and is suggested to represent the 'parent' estrogen of NP. Benzoylation of r uterotrophic activity, in contrast to the enhancing effect of benzoylation on estradiol.
Selected chemicals shown to be active in the immature rat uterotrophic assay were also evaluated in an in vitro yeast human estrogen receptor transactivation assay. Most of the chemicals gave similar qualitative responses to those seen in the uterotrophic assay, and the detection of the estrogen methoxychlor by the yeast assay evidenced a degree of intrinsic metabolic competence. However, the assay had a reduced ability (compared to rodents) to hydrolyse the benzoate ester of estradiol, and the estrogenic benzoate derivative of NP was not active in the yeast assay. These last results indicate that current metabolic deficiencies of in vitro estrogenicity assays will limit the value of negative data for the immediate future.
The results described illustrate the intrinsic complexity of evaluating chemicals for estrogenic activities and confirm the need for rigorous attention to experimental design and criteria for assessing estrogenic activity.
INTRODUCTION
There is concern that some natural and synthetic chemicals have the potential to disturb normal sexual differentiation/development in animals and humans (Colborn and Clement, 1992; McLachlan, 1993; McLachlan and Korach, 1995) . The ability of some chemicals to elicit an estrogenic response in intact organisms forms one of the primary mechanisms by which such adverse effects could be produced (McLachlan and Korach, 1995) . One of the most extensively used assays for estrogenic activity is the rodent uterotrophic assay in which the ability of chemicals to stimulate uterine growth is monitored (Reel et al., 1996; O'Connor et al., 1996) . There are a variety of protocols described for this assay, including the use of rats or mice; immature, hypophysectomized or ovariectomized animals, and the use of oral or subcutaneous routes of chemical administration. Given that most toxicity studies are currently conducted in rats, using the oral route of administration, we decided to evaluate the utility of the immature rat uterotrophic assay, using the oral route of chemical administration, as an in vivo assay for estrogenic activity. An associated objective was to discern the critical features of the assay protocol.
Having confirmed the practicality of the immature rat uterotrophic assay it was used to study a range of reference hormonally active chemicals and to elucidate the chemical basis for the estrogenic activity reported for branched chain relationship between estrogenic activities observed in vitro, and those observed in vivo, some of the chemicals found positive in the uterotrophic assay were evaluated in the yeast human estrogen receptor (hER) transactivation assay described by Routledge and Sumpter (1996) .
MATERIALS AND METHODS

Chemicals
Estradiol (E 2 ; for chemical structures, see Scheme 1), ethinyl estradiol (EE), cyproterone acetate (CPA), methoxychlor (MC; 98%), corn oil and arachis oil were obtained from Sigma (Poole, Dorset, UK). Estradiol benzoate (E 2 B) was obtained from Intervet (Cambridge, UK) as a solution in arachis oil (peanut oil). Coumestrol was obtained from Apin Chemicals (Abingdon, Oxfordshire, UK) and ICI 182,780 was a gift from Dr A Wakeling, Zeneca Pharmaceuticals (Alderley Park, Macclesfield s obtained from two Dorset, UK; 85% para isomers: NP(F)] s, USA; 94.2%: NP(S)]. NMR analysis of these (nNP; 98%) was obtained from Lancaster synthesis (Morecambe, Lancashire, UK). The benzoate ester of NP(F), (NPB), was prepared by standard benzoylation of the parent phenol (NP; Fluka). The structural integrity of the oily product was confirmed by NMR spectroscopy and elemental analysis. The benzoate ester of nNP (nNPB) was prepared by benzoylation of the parent phenol (nNP; source as above).
o . NMR and mass spectroscopy confirmed its structure and elemental analysis indicated that it 2 ] was synthesized from estrone by the method described by Francois and Levisalles (1968 
Uterotrophic assays
The protocol for the uterotrophic assays was based on that described by Wakeling et al., (1991) . Animals were dosed by either oral gavage or subcutaneous (sc) injection. Test agents were dissolved or homogeneously suspended in arachis oil (except where indicated otherwise). The dosing volume for both routes of exposure was 5ml/kg body weight, except for the assays of coumestrol where a dosing volume of 10ml/kg was used. Animals received 3 daily doses of the test compound and were killed by an overdose of halothane 24h after the final dose. The dose levels shown in the Figures are the daily dose levels. Vaginal opening (or otherwise) was recorded at the time of death. Uteri were excised, trimmed free of fat, pierced and blotted to remove excess fluid. The body of the uterus was cut just above its junction with the cervix and at the junction of the uterine horns with the ovaries. The uterus was then weighed (wet weight). Uterine dry weight was also determined by drying the uteri at 70 o et al., 1988) . Dose levels were usually selected based on previous findings for estradiol, and in the case of those chemicals giving positive uterotrophic responses, the maximum tolerated dose (MTD) was probably not achieved. The top dose level of NP evaluated (285 mg/kg) was the MTD (data not shown). The analogs of NP were evaluated to this same top dose level. The top dose level of cyproterone acetate E 2 ,or E 2 B, was used as a positive control agent in all of the studies, and each study was accompanied by a vehicle (negative) control group. Uterus wet weights are shown in the Figures, but uterus dry weights and uterus weight/body weight data were derived routinely and are discussed in the text. Generally, five animals per exposure group were employed, but this number was increased in some cases (see Figures) .
Yeast assays
The yeast assay for estrogenic activity of chemicals, as described by Routledge and Sumpter (1996) , has the DNA sequence of hER incorporated into the yeast genome. The molecular construct was designed to allow the activated sequences contained within a strong promoter region of an expression plasmid. When an active ligand binds to the estrogen receptor a lacZ reporter gene expresses the enzyme galactosidase, which itself is quantitated using a chromogenic substrate. The methods used were exactly as described earlier (Routledge and Sumpter, 1996) . Briefly, the test chemicals were dissolved in ethanol and added to 96 well plastic plates at the concentrations shown in Figure 15 . The ethanol was allowed to evaporate before the addition of medium containing the yeast . The plates were incubated at 32 for 4 days and quantitated in terms of the absorbance of wells at 540 nm. Vehicle and estradiol controls accompanied each experiment, and representative data are shown.
RESULTS AND DISCUSSION
The results and discussion are presented in relation to the three topics evaluated in this study. Chemical structures are shown in Scheme 1.
Critical protocol features of the uterotrophic assay
Estradiol benzoate (E 2 crease in uterus weights in animals 27 days at the start of the experiment had developed uteri and failed to respond further to the estrogenic challenge (Figure 1 ). Vaginal opening showed the same trend. The uterus we days at the end of the experiment were identical (Figure 1 ) despite a 20% difference in body weight at termination (data not shown). These observations indicate that uterotrophic assays absolute uterus weight is probably a better index of uterine growth than the uterus/body weight index (see later for extension of the latter point).
Comparisons of the oral and sc routes of administration of the three established estrogens estradiol (E 2 ), estradiol benzoate (E 2 E 2 is more active in the uterotrophic assay when injected subcutaneously, but a similar maximal effect can be achieved following oral 2). Based on these combined results, oral administration of 400 g/kg of the endogenous estrogen E 2 was adopted as the standard positive control agent for the uterotrophic assay. The relationship between uterus wet weights, uterus wet weights relative to body weight, and uterus dry weights was essentially constant for all of the animals in the present study, and representative data for animals exposed to E 2 are shown in Table 1 . Uterus wet weights expressed relative to body weights are subject (Ashby et al., 1997c) , as illustrated by the slightly larger uterus/body weight ratio for animals exposed to the highest s.c. dose of E 2 , an effect dependant upon a small reduction in body weight for these animals (Table 1) . We decided to regard absolute uterus wet weights as the primary assay parameter, with recourse to the determination of uterus dry weights in cases where it was considered necessary to confirm that a weak uterotrophic assay response was not due totally to increased water imbibation (c.f. such a suggestion; Evans et al., 1996) .
The enhanced sensitivity of the uterotrophic assay to E 2 when using sc injection, as opposed to oral administration, was also observed for both E 2 cutaneously administered EE was the most potent estrogen encountered in the present study, showing trophic activity at 0.5 g/kg. The choice of route of administration for chemical studies will be influenced by the purpose for which the data are to be used. Oral administration is generally employed in chemical toxicity studies to be employed for human risk assessments, and it seems reasonable to stay with this route for routine toxicity studies. In some cases, such as when the shape of the dose response relationship is the critical issue, it may be appropriate to employ parenteral administration, but it would be inappropriate to use such routes routinely, especially if the only justification for that is that these routes have been used historically. The specificity of the uterotrophic assay for estrogens was indicated by the (Neumann, 1977; Figure 5 ).
The observation that premature vaginal opening appears to be a less sensitive marker of estrogenic activity than does the stimulation of uterine growth (Reel et a.,l 1996) has been
In particular, premature vaginal opening does not always parallel increases in uterine weight. For example, at doses giving approximately equivalent uterotrophic effects, orally administered E 2 and EE produced premature vaginal did not. To date, none of our control rats has had an open vagina at the time of th nonetheless, some chemicals produce a clear uterotrophic effect in the absence of vaginal opening (see coumestrol, later herein). This indicates that while premature vaginal opening can strengthen the classification of an agent as an estrogen, it cannot be taken as a definitive requirement.
The uterotrophic response produced by E 2 estrogen receptor antagonist ICI 182,780 (Wakeling and Valcaccia, 1983) when the latter was administered concomitantly with each dose of E 2 estrogens can be detected using the uterotrophic assay by the simple expedient of challenging the assay positive control agent with the test chemical. Animals exposed to ICI 182,780, with or without E 2 , gave uterus weights that were decreased by ~50% when compared to concurrent control values. This led us to evaluate whether either the test vehicle, or the test diet, contained estrogenic contaminants. First, we evaluated whether the arachis oil vehicle was itself weakly estrogenic, some vegetable oils being known to contain phytoestrogens (Gunstone et al., 1994) . The data shown in Figure 7 confirm that there was no difference in the uterus weights of untreated, arachis oil treated, or distilled water treated rats. In each case, ICI 182,780 gave an approximately 50% reduction in uterus weights compared to concurrent controls. This indicated either that low levels of endogenous estrogens, or dietary phytoestrogens, were responsible for the elevated control uterus weights. The uterotrophic activity of the phytoestrogen coumestrol (Markarevich et al., 1995) (Figure 8 ) confirmed that estrogenic dietary contaminants have the potential to influence control uterus weights in uterotrophic assays. The data shown in Figure 9 confirmed that dietary estrogens were the probable reason why our control uterus weights could be reduced by administration of ICI 182,780. Based on these data, the R&M no.3 / R&M no.1 diet combination was adopted for routine use with the assay. However, the experiments discussed in this paper were conducted before that change of diet occurred, thus the relatively high control uterus weights observed herein. Overall, the data shown in Figure 9 underline that diet should be considered as an important variable in any endocrine disruption assay, and that care should be taken to specify its source and constitution.
The rat was selected as the primary test species for the present studies. However, the mouse has been used equally in the past, and the general sensitivity and utility of the mouse uterotrophic assay was recently confirmed by Shelby et al. (1996) . One of the xenobiotic estrogens evaluated by Shelby et al. , methoxychlor (MC), was found to be inactive in the two in vitro estrogenicity assays employed, probably because of the inability of these systems to remove the methyl groups of MC to yield the active diphenolic estrogenic species (Bulger et al. 1978) . In fact, Shelby et al. (1996) demonstrated the latter diphenol to be estrogenic in vitro. In contrast, these authors reported MC to be uterotrophic to the mouse . The data shown in Figure 10 reveal that MC shows similar uterotrophic activity in the rat and the mous administration. Shelby et al. (1996) expressed their uterotrophic assay data corrected for body weight, and when the mouse data shown in Figure 10 are similarly corrected, MC is found to have given a positive response of similar increase in uterus weights over concurrent control levels, at 500 mg/kg MC). These limited data for MC suggest that the choice of test species and route of chemical administration may only lead to quantitative, rather than qualitative, differences in uterotrophic assay outcomes. However, qualitatively different test results will inevitably emerge for chemicals that are differentially absorbed and/or differentially metabolized in different test species. The choice of test species and route of administration for the uterotrophic assay should be kept under review as new data accumulate.
Structural basis of the estrogenicity of nonylphenol
isomers. The commercial material is known to possess estrogenic properties (Soto et al., 1995; Routledge and Sumpter, 1997) , and these have been suggested to arise due to the structural similarity to E 2 of one or more of the isomers of NP. Warhurst (1994) has suggested one particular isomer of NP as being the most likely to bind to and activate the estrogen receptor (Scheme 1). This isomer happens to be similar in structure to octylphenol, a related compound that contains only one isomer (as shown in Scheme 1) and which is active as an estrogen in vitro (Routledge and Sumpter, 1997) and in vivo (Bicknell et al., 1995) . Recently, Sanborn (1996) erroneously associated the estrogenic properties of commercial NP with the linear aliphatic sidechain isomer nNP, a compound which is not estrogenic (see below). Sanborn (1996) also suggested that hydroxylation of the aliphatic sidechain of nonylphenols (shown for nNP in Scheme 1) was required to complete their structural alignment with E 2 . However, that suggestion is not supported by the observation that NP, per se, competes with E 2 in bindings to isolated cytosolic estrogen receptors, i.e., without the need for prior metabolic transformation (Soto et al., 1995; White et al., 1994) .
As recently reported by Lee and Lee (1996) , NP immature rat uterotrophic assay (Figure 11 ). This response was abolished by antagonist ICI 182,780, thereby confirming that the effect was mediated via the estrogen receptor (Figure 11 ). Similar levels of uterotrophic activity were observed for the two different sa (Figure 12 ). The inactivity of the straight chain analog of NP (nNP; Figure 12 ) was supported by its inactivity in the yeast assay (see below). The inactivity of nNP favors the in NP is important to the interaction of the chemical with the estrogen receptor (Routledge and Sumpter, 1997; Warhurst, 1994) . It is interesting to note the weak assay responses for NP shown in Figure 12 . The reproducibility of these weak effects, and the observation of cases of vaginal opening among the test animals, establish uterotrophic activity in these cases; nonetheless, these data indicate the urgent need to agree criteria for discerning activity in the uterotrophic assay (Ashby et al., 1997c) .
It was noted earlier that E 2 B is a more potent estrogen in the uterotrophic assay than is E 2 itself (Figures 2 and 3 ). This enhancement of activity is probably caused by a combination of factors, such as reduced conjugative excretion of the free phenol (E 2 ) by protection of its acidic phenol substituent, and the enhanced lipophilicity of the benzoate (E 2 B) in comparison to the parent phenol (E 2 ). It therefore became of interest to evaluate if the benzoate derivative of NP (NPB) would be more potent than NP itself, and in particular, if the benzoate derivative (nNPB) of the inactive st in the uterotrophic assay. The data shown in Figure 13 demonstrate that these two benzoates were of similar activity to the parent phenols; equally as positive, and negative, respectively. These rather surprising findings indicate that th estradiol cannot be generalized, and that nNP seems to be devoid of intrinsic estrogenic activity.
The suggestion that the estrogenic activity of NP is due to the ability of some of its constituent isomers to mimic estradiol in binding to the estrogen receptor (Routledge and Sumpter, 1997; Warhurst, 1994) indicates that the 17 2 ) should represent the progenitor 'est 2 is reported to be uterotrophic to hypophysectomised rats (Huggins and Jensen, 1955) and to be able to compete with estradiol in binding to isolated estrogen receptors (Fanchenko et al., 2 2 was uterotrophic to immature rats (Figure 14) , showing a slightly higher minimum detection level than E 2 and a more flattened dose response relationship (Figures 3 and 14) . As 2 2 B) showed similar activity in the uterotrophic assay to 2 ; Figure 14) . It therefore appears that the suggestion that one or more of the branched chain isomers of NP is able to mimic estradiol in binding to the estrogen receptor is a valid and useful observation, 2 However, the suggestion that the aliphatic sidechain of NP requires to be hydroxylated before NP acquires estrogenic activity (Sanborn, 1996) seems to be unlikely.
Relative sensitivity of the yeast estrogenicity assay and the uterotrophic assay
In vitro assays will be of particular value in cases where a lead chemical showing estrogenic activity is shown to be positive in the in vitro assay, and where the activity of structural analogs of the lead chemical are the subject of study. The yeast hER assay described by Routledge and Sumpter (1996) , has shown sensitivity to a wide range of chemical classes of estrogens, and the assay has intrinsic metabolic competence, as evidenced by its ability to detect as positive the estrogen MC (Figure 15 ; Ashby et al., 1997b) , despite the inability of some other in vitro assays to detect it (Shelby et al., 1996) . This attribute of the yeast assay is probably due to the enhanced metabolic competence of growing yeast cells and their presumed ability to demethylate MC to the active estrogenic diphenol derivative et al., 1996; Bulger et al., 1978) . As expected, the yeast assay was more sensitive to the ultimate estrogenic species to MC itself ( Figure 15 ). (Figure 15 ). This reduced activity is consistent with 2 and E 2 in the 2 in vitro and in vivo has implications for the derivation of structure activity relationships among xenobiotic estrogens (Katzenellenbogen, 1995; Waller et al. hydroxy and the 17 considered to be necessary for estrogenic activity.
The yeast assay is less sensitive to E 2 B than it is to E 2 ( Figure 15 ). This is in contrast to the marginally enhanced activity of E 2 B, compared to E 2 , in the uterotrophic assay (Figures 2  and 3 ). This indicates that the yeast assay is group present in E 2 B, but that this is not completed under the conditions of the test. As observed with the uterotrophic assay, the yeast assay found the two different samples of NP to be of similar estrogenic activity, and nNP to be inactive (Figure 15 ). In surprising contrast to in the uterotrophic assay, the benzoate derivative of NP (NPB) was inactive in the yeast assay ( Figure 13 ). This suggests that the yeast cells possess only selective esterase activity, being able to hydrolyse partially the benzoate ester of E 2 B, while being unable to hydrolyse the benzoate ester of NPB.
In summary, the yeast estrogenicity assay has demonstrated high general sensitivity, and a level of metabolic competence, in the present studies. A potential weakness of this (and probably of all other in vitro assays) is highlighted by the failure of the yeast assay to detect as positive the in vivo estrogen NPB. That failure is perhaps reflected quantitatively by the reduced sensitivity of the assay to E 2 B in comparison to E 2 . Although the problem posed by the inadequate metabolic competence of the current in vitro estrogenicity assays must be solved before they can achieve their true potential (Ashby et al., 1997a; Ashby, 1997) , the partial metabolic competence of the present yeast assay confirms it as a valuable screening test.
CONCLUSIONS
The results described here illustrate the intrinsic complexity of evaluating chemicals for estrogenic activities. Suitable detection systems exist, but the manner in which they are deployed can influence the toxicological value of the data derived. It is recommended that when designing experiments in this area of toxicology it is important consider the purposes for which the test data will be used. This will influence practical decisions, such as choice of in vitro or in vivo assays, and the choice of dose levels and route of chemical administration in rodent studies. At the practical level, there is an urgent need to agree criteria for assessing the activity of chemicals in the available estrogenicity assays, and to enhance the metabolic competence of the currently available in vitro assays. 
